Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:saroglitazar
|
| gptkbp:approvalYear |
2013
|
| gptkbp:approvedBy |
gptkb:India
|
| gptkbp:brand |
gptkb:saroglitazar
|
| gptkbp:compatibleWith |
gptkb:European_Union
gptkb:United_States |
| gptkbp:developedBy |
gptkb:Zydus_Cadila
|
| gptkbp:firstBook |
yes
|
| gptkbp:form |
gptkb:tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Lipaglyn
|
| gptkbp:indication |
gptkb:type_2_diabetes
hypertriglyceridemia |
| gptkbp:marketedAs |
gptkb:Zydus_Cadila
|
| gptkbp:mechanismOfAction |
PPAR alpha/gamma agonist
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:usedFor |
hyperlipidemia
diabetic dyslipidemia |
| gptkbp:bfsParent |
gptkb:Zydus_Cadila
|
| gptkbp:bfsLayer |
6
|